Charles River Promotes Cardiovascular Health Awareness with Support for the American Heart Association
Charles River Laboratories International, Inc. (NYSE: CRL) has announced a new collaboration with the American Heart Association, a globally recognized leader in advancing heart and brain health. This partnership is designed to strengthen efforts aimed at raising awareness of cardiovascular disease, promoting prevention strategies, and supporting community-based health initiatives that can improve outcomes for populations at risk.
The collaboration reflects a growing recognition across both the public and private sectors that cardiovascular disease remains one of the most pressing global health challenges. Despite advances in medical research, diagnostics, and treatment, the burden of heart-related conditions continues to impact millions of individuals and families worldwide. By joining forces, Charles River and the American Heart Association aim to combine scientific expertise, community outreach, and education to address these ongoing challenges more effectively.
Kristen Eisenhauer, Chief Commercial Officer at Charles River Laboratories International, Inc., emphasized the urgency of the issue, pointing to recent data highlighting the continued toll of cardiovascular disease. She noted that the latest findings reinforce the importance of sustained investment in prevention, education, and science-driven innovation. According to Eisenhauer, supporting initiatives that improve awareness and encourage healthier lifestyles is essential to maintaining progress and reducing the long-term impact of cardiovascular conditions.
As part of this collaboration, Charles River will provide support for the American Heart Association’s Heart of Boston campaign. This initiative is focused on improving cardiovascular health outcomes across the Greater Boston region while also contributing to broader national efforts. The campaign emphasizes community engagement, equitable access to healthcare resources, and the promotion of preventive measures such as healthy eating, physical activity, and regular health screenings.
The partnership aligns closely with Charles River’s corporate mission, “Together, We Create Healthier Lives,” as well as its broader Corporate Citizenship strategy. While the company is widely known for its role in supporting drug discovery and development, this collaboration highlights its commitment to advancing human health beyond the laboratory setting. By engaging in community-focused initiatives, Charles River is extending its impact from preclinical research into real-world health improvement efforts.
At the same time, the American Heart Association continues to play a central role in shaping public health strategies through research, advocacy, and education. Its campaigns are designed not only to inform individuals about risk factors but also to drive systemic changes that can improve health outcomes at the population level. The Heart of Boston campaign exemplifies this approach by combining local engagement with broader national goals.
The timing of this collaboration is particularly significant in light of the American Heart Association’s 2026 Heart Disease and Stroke Statistics Update. The report underscores that heart disease remains the leading cause of death in the United States, while stroke ranks as the fourth-leading cause. Together, these conditions account for more than one in four deaths across the country, illustrating the scale and persistence of the challenge.
Although recent data suggests a modest decline in total cardiovascular-related deaths following increases during the COVID-19 pandemic, the overall burden remains high. The pandemic itself had exacerbated many underlying risk factors, including reduced access to routine healthcare, disruptions in physical activity, and increased stress levels. As a result, the need for renewed focus on cardiovascular health has become even more apparent.
The American Heart Association’s findings also highlight the continued prevalence of key risk factors such as high blood pressure, diabetes, and obesity. These conditions significantly increase the likelihood of developing cardiovascular disease and are often influenced by lifestyle, socioeconomic factors, and access to healthcare. Addressing these risk factors requires a multifaceted approach that includes education, early detection, and long-term behavior change.
Through their collaboration, Charles River Laboratories International, Inc. and the American Heart Association aim to tackle these issues by promoting awareness and encouraging preventive action. Public education campaigns will play a key role in helping individuals understand their risk and take proactive steps to improve their health. This includes adopting healthier diets, increasing physical activity, managing stress, and seeking regular medical care.
Equally important is the role of research and innovation in advancing cardiovascular health. Charles River’s expertise in preclinical and clinical research positions it to contribute valuable insights into the development of new therapies and interventions. By supporting the American Heart Association’s initiatives, the company is helping to bridge the gap between scientific discovery and real-world application.
Community engagement is another cornerstone of the partnership. By working with local organizations and stakeholders, the Heart of Boston campaign seeks to ensure that health resources and information reach diverse populations, including those who may face barriers to care. This focus on equity is critical, as cardiovascular disease disproportionately affects certain communities due to factors such as income, education, and access to healthcare services.
Ultimately, this collaboration represents a shared commitment to improving cardiovascular health through a combination of science, education, and community action. By leveraging their respective strengths, Charles River Laboratories International, Inc. and the American Heart Association are working to address one of the most significant public health challenges of our time.
As the partnership moves forward, its success will depend on sustained engagement, continued investment in research and prevention, and the ability to translate knowledge into meaningful change. With cardiovascular disease continuing to affect millions of lives, initiatives like this play a vital role in building healthier communities and reducing the global burden of heart-related conditions.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them.
Source Link:https://www.businesswire.com/
